Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2014

View Archived Issues

High-throughput screening for novel GPR103 antagonists as anorexigenics

RedHill Biopharma reports preclinical data for RHB-104 in type 1 diabetes

Cannabis Technologies reveals CTI-085 for the treatment of glaucoma

Antibe initiates phase I study of ATB-346

Sanofi K.K. announces new alliance

First results presented from phase II study of dalantercept in advanced renal cell carcinoma

Phase I evaluation of an immunogenic cell death inducer for transdermally accessible tumors

SoluMatrix meloxicam reduces osteoarthritis pain in phase III trial

Gilead Sciences files for approval of sofosbuvir in Japan

Molecular Partners reports erbB-2-targeting DARPins

Ixogen discloses new oncolytic adenoviruses

Basilea provides update on the U.S. regulatory status of ceftobiprole

Vertex receives positive CHMP opinion to expand Kalydeco approval

Roche synthesizes novel SCD inhibitors

Regorafenib recommended for approval in Europe for GIST

Data reported on ABT-981 in healthy subjects and patients with knee osteoarthritis

CSIR patent describes new Bcl-2 inhibitors/BAX activators

Janssen-Cilag seeks to expand Velcade label in Europe

A*STAR reports development of Mnk1/2 and ABL inhibitors

Vizamyl recommended for approval in E.U.

Ischemix enrolls first patient in phase IIa trial to prevent contrast-induced kidney injury

Bristol-Myers Squibb receives positive CHMP opinion for Daklinza

FDA approves inhaled insulin for type 1 diabetes

Auxilium plans merger with QLT

EMA's CHMP recommends new approval for Eliquis

EMA committee recommends approval of Abasria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...